Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01790126 · ClinicalTrials.gov registry record · Phase 2
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
A Phase 2 study, sponsored by Aragon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT01790126 is a Phase 2 study that has completed, run by Aragon Pharmaceuticals. The registered enrollment target is 90 participants.
The verdict
NCT01790126, a Phase 2 study, has completed, sponsored by Aragon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The proposed clinical trial will study the effects of 12 months of therapy with ARN-509 alone, or in combination with an LHRH agonist (LHRHa), each compared with LHRHa alone, in men with a rapidly rising serum PSA after prior definitive local therapy for prostate cancer. The endpoints selected reflect measurable short term effects of androgen deprivation therapy (ADT), including quality of life and several metabolic parameters. In addition, the relative effect of each treatment strategy on PSA suppression as well as testosterone recovery (and subsequent PSA progression) after 12 months of therapy will be evaluated.
Interventions
- DRUG LHRH Agonist
- DRUG ARN-509
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2013-03-04 |
| Est. Completion | 2019-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01790126
The ClinicalTrials.gov registry entry for NCT01790126 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aragon Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LHRH Agonist is the first listed.
NCT01790126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01790126 about?
NCT01790126 is a clinical study titled "The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer". The proposed clinical trial will study the effects of 12 months of therapy with ARN-509 alone, or in combination with an LHRH agonist (LHRHa), each compared with LHRHa alone, in men with a rapidly rising serum PSA after prior definitive local therapy for prostate cancer. The endpoints selected refle...
What is the current status of trial NCT01790126?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2013-03-04. Estimated completion is 2019-03-01.
What interventions are being tested in trial NCT01790126?
The interventions under investigation include: LHRH Agonist (DRUG), ARN-509 (DRUG).
Who is sponsoring clinical trial NCT01790126?
This trial is sponsored by Aragon Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.